atezolizumab + RO6958688

Atezolizumab + RO6958688 is an investigational combination therapy for advanced solid tumors, specifically carcinoembryonic antigen (CEA)-positive cancers such as metastatic colorectal cancer. - **Atezolizumab** is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), enhancing anti-tumor immunity by preventing tumor-induced T-cell suppression. - **RO6958688 (CEA CD3 TCB, RG7802)** is a bispecific monoclonal antibody designed to bridge T cells (via CD3) to CEA-expressing tumor cells, promoting targeted T-cell killing of tumor cells and increasing intra-tumoral T cell infiltration and activation. The combination aims to augment immune-mediated anti-tumor activity, with RO6958688 driving T-cell recruitment and activation within tumors, and atezolizumab blocking immune checkpoint signaling. Preclinical evidence shows increased PD-1/PD-L1 activity after RO6958688, supporting rationale for this combination. Development is led by Roche/Genentech, and clinical studies are ongoing assessing safety, dosing, and anti-tumor efficacy[3][4].

Brand names

atezolizumab (brand: Tecentriq)

Other names

Tecentriq (atezolizumab)CEA CD3 TCB (RO6958688)